BOLD vs. ZNTL, CVAC, ETNB, CNTA, PRTC, COGT, EOLS, PLRX, PRAX, and NRIX
Should you be buying Audentes Therapeutics stock or one of its competitors? The main competitors of Audentes Therapeutics include Zentalis Pharmaceuticals (ZNTL), CureVac (CVAC), 89bio (ETNB), Centessa Pharmaceuticals (CNTA), PureTech Health (PRTC), Cogent Biosciences (COGT), Evolus (EOLS), Pliant Therapeutics (PLRX), Praxis Precision Medicines (PRAX), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical preparations" industry.
Audentes Therapeutics (NASDAQ:BOLD) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability, valuation and community ranking.
Audentes Therapeutics' return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.
Audentes Therapeutics received 418 more outperform votes than Zentalis Pharmaceuticals when rated by MarketBeat users. Likewise, 69.22% of users gave Audentes Therapeutics an outperform vote while only 65.00% of users gave Zentalis Pharmaceuticals an outperform vote.
In the previous week, Zentalis Pharmaceuticals had 3 more articles in the media than Audentes Therapeutics. MarketBeat recorded 5 mentions for Zentalis Pharmaceuticals and 2 mentions for Audentes Therapeutics. Zentalis Pharmaceuticals' average media sentiment score of 0.65 beat Audentes Therapeutics' score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.
Audentes Therapeutics presently has a consensus price target of $23.00, suggesting a potential upside of 139.58%. Zentalis Pharmaceuticals has a consensus price target of $31.67, suggesting a potential upside of 167.00%. Given Zentalis Pharmaceuticals' higher possible upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Audentes Therapeutics.
Summary
Audentes Therapeutics beats Zentalis Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
Get Audentes Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Audentes Therapeutics Competitors List
Related Companies and Tools
